Trial results

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

NCT07820358 on ClinicalTrials.gov · last registry update 2026-10-01

A small phase 2 — 48 participants, against a typical 110. Due to report 31 December 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Pathological Response Rate. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

The Methodist Hospital Research Institute

Sponsor type

Other

Enrollment

48

Started

2027-01-01

Primary completion

2028-12-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Pathological Response Rate

Conditions studied

Endometrial Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Cancer Stage I · Endometrial Cancer · Fertility-Sparing Treatment (FST) · Obesity & Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.